Caprock Group LLC Cuts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Caprock Group LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,296 shares of the biopharmaceutical company’s stock after selling 90 shares during the quarter. Caprock Group LLC’s holdings in Regeneron Pharmaceuticals were worth $1,362,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Brown Lisle Cummings Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 18.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 10 shares in the last quarter. Sachetta LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Adirondack Trust Co. boosted its holdings in shares of Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 10 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 10 shares in the last quarter. Finally, Western Financial Corp CA lifted its stake in shares of Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock valued at $1,912,000 after acquiring an additional 12 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.2 %

REGN stock opened at $743.35 on Thursday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $736.01 and a fifty-two week high of $1,211.20. The business’s 50 day moving average price is $961.76 and its two-hundred day moving average price is $1,030.14. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a market capitalization of $81.69 billion, a price-to-earnings ratio of 18.40, a price-to-earnings-growth ratio of 2.86 and a beta of 0.15.

Wall Street Analyst Weigh In

REGN has been the subject of a number of recent research reports. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Barclays lowered their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Finally, JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insiders Place Their Bets

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 27.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.